# General Proximity **Source:** https://geo.sig.ai/brands/general-proximity **Vertical:** Healthcare **Subcategory:** General **Tier:** Emerging **Website:** generalproximity.com **Last Updated:** 2026-04-14 ## Summary Cambridge MA YC W20 induced proximity medicines (molecular glues/PROTACs) targeting undruggable proteins; $16M Series A Jan 2025 Tomales Bay Capital competing with Arvinas and C4 Therapeutics for protein degradation oncology platform. ## Company Overview General Proximity is a Cambridge, Massachusetts-based biotechnology company — backed by Y Combinator (W20) with $16 million in Series A funding in January 2025 led by Tomales Bay Capital — pioneering induced proximity medicines that work by bringing together disease-causing proteins to trigger their degradation or modulation, representing a next-generation therapeutic modality beyond traditional small molecule inhibitors and biologics. Founded in 2020, General Proximity combines computational chemistry, medicinal chemistry, and structural biology to design molecular glues and PROTACs (proteolysis-targeting chimeras) for previously undruggable targets in oncology and other disease areas — targeting the protein degradation mechanisms that cells use naturally to eliminate aberrant proteins. General Proximity's induced proximity platform addresses the fundamental limitation of conventional drug design: traditional small molecule drugs work by occupying the active site of a disease-relevant protein to block its function (enzyme inhibition, receptor antagonism) — but this approach only works for 10-15% of disease-relevant proteins that have accessible binding pockets. The remaining 85%+ are 'undruggable' by conventional methods. Induced proximity medicines (molecular glues and PROTACs) work differently — rather than blocking a protein, they recruit the cell's own protein degradation machinery (the ubiquitin-proteasome system) to tag and eliminate the disease-causing protein entirely. This catalytic mechanism (one drug molecule can degrade multiple copies of the target protein) enables sub-nanomolar efficacy at low drug doses, and the protein elimination approach provides durable target engagement that inhibition-based drugs cannot achieve. General Proximity's computational platform accelerates the design of these ternary complex-forming molecules by predicting which molecular configurations will successfully recruit the degradation machinery to the target protein. In 2025, General Proximity competes in the induced proximity, molecular glue, and protein degradation drug discovery market with C4 Therapeutics (NASDAQ: CCCC, PROTAC-based oncology, $600M raised), Arvinas (NASDAQ: ARVN, PROTAC platform, $1B+ raised), and Kymera Therapeutics (NASDAQ: KYMR, protein degradation, $700M+ raised) for precision oncology and targeted protein degradation drug development platform adoption. Tomales Bay Capital's Series A leadership reflects biotech venture conviction in the induced proximity modality. Y Combinator W20 backing (unusual for a biotech company in YC) connects General Proximity with the computational biology and AI drug discovery investment community. The 2025 strategy focuses on advancing the lead oncology programs toward IND-enabling studies, building the AI-assisted ternary complex structure prediction for accelerated molecular glue design, and expanding the disease area pipeline beyond oncology to targeted protein degradation in neurodegeneration and inflammatory diseases. ## Frequently Asked Questions ### What is General Proximity? General Proximity is a biotechnology company founded in 2020 that pioneers induced proximity medicines for treating diseases. The San Francisco-based company develops molecular glues and PROTACs that work by bringing together disease-causing proteins to trigger their degradation or modulation, representing a new therapeutic modality beyond traditional small molecules and biologics. ### What products and services does General Proximity offer? General Proximity offers induced proximity medicines including molecular glue development and PROTAC therapeutics. The company also provides a computational drug design platform focused on protein degradation therapeutics for previously undruggable targets. ### Who are General Proximity's target customers? General Proximity focuses on developing therapeutics for patients with oncology and other disease areas. The company targets previously undruggable disease-causing proteins that cannot be addressed by traditional small molecules and biologics. ### When was General Proximity founded? General Proximity was founded in 2020. The company was part of Y Combinator's Winter 2020 (W20) batch. ### Where is General Proximity located? General Proximity is based in San Francisco, California. ### What funding has General Proximity raised? General Proximity raised $16 million in Series A funding in January 2025, led by Tomales Bay Capital. The company was previously backed by Y Combinator as part of their W20 batch. ### What are General Proximity's key achievements? General Proximity successfully raised $16M in Series A funding in January 2025 and has developed a platform for designing protein degradation therapeutics. The company is pioneering induced proximity medicines for previously undruggable targets in oncology and other disease areas. ### What technology and approach does General Proximity use? General Proximity's platform combines computational chemistry, medicinal chemistry, and structural biology to design molecular glues and PROTACs. This approach enables the company to target previously undruggable proteins by inducing their degradation or modulation. ### How can I contact General Proximity? General Proximity is located in San Francisco, CA. Specific contact information is not provided in the available company information. ### What are General Proximity's recent developments? In January 2025, General Proximity raised $16 million in Series A funding led by Tomales Bay Capital. The company continues to advance its platform for designing protein degradation therapeutics targeting oncology and other disease areas. ## Tags healthtech, saas, north-america, b2b --- *Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*